These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 35213293)

  • 1. Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies.
    Green TC; Bratberg J; Irwin AN; Boggis J; Gray M; Leichtling G; Bolivar D; Floyd A; Al-Jammali Z; Arnold J; Hansen R; Hartung D
    Subst Abus; 2022; 43(1):901-905. PubMed ID: 35213293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Examining the effects of COVID-19 on pharmacy dispensing of naloxone and syringes sales across Massachusetts and New Hampshire.
    Bolivar D; Hartung D; Silcox J; Bratberg J; Boggis J; Rabin M; Green TC
    J Am Pharm Assoc (2003); 2023; 63(1):330-335.e1. PubMed ID: 36369076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "I go out of my way to give them an extra smile now:" A study of pharmacists who participated in Respond to Prevent, a community pharmacy intervention to accelerate provision of harm reduction materials.
    Irwin AN; Gray M; Ventricelli D; Boggis JS; Bratberg J; Floyd AS; Silcox J; Hartung DM; Green TC
    Res Social Adm Pharm; 2024 May; 20(5):512-519. PubMed ID: 38395644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015.
    Stopka TJ; Donahue A; Hutcheson M; Green TC
    J Am Pharm Assoc (2003); 2017; 57(2S):S34-S44. PubMed ID: 28189540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Like it was just everyday business": A qualitative study of pharmacy-based naloxone and syringe customer experience.
    Gray M; Shin SS; Silcox J; Flores D; Bolivar D; Irwin AN; Floyd AS; Bratberg J; Boggis JS; Hartung DM; Green TC
    J Am Pharm Assoc (2003); 2023; 63(3):838-846. PubMed ID: 36872182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
    Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
    Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Readiness of community pharmacies to implement an opioid safety intervention.
    Floyd AS; Silcox J; Cousin E; Irwin AN; Gray M; Bolivar D; Bratberg J; Arnold J; Al-Jammali Z; Hansen RN; Hartung DM; Green TC
    J Am Pharm Assoc (2003); 2023; 63(1):275-283.e1. PubMed ID: 36496310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.
    Santa HM; Amirova SG; Ventricelli DJ; Downs GE; Nowalk AA; Pringle JL; Aruru M
    Am J Health Syst Pharm; 2021 Feb; 78(4):327-335. PubMed ID: 33336254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependence.
    Raisch DW; Fudala PJ; Saxon AJ; Walsh R; Casadonte P; Ling W; Johnson BA; Malkerneker U; Ordorica P; Williford WO; Sather MR
    J Am Pharm Assoc (2003); 2005; 45(1):23-32. PubMed ID: 15730114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of a statewide community pharmacy approach to opioid harm reduction.
    Sexton SM; Marciniak MW; Gatton O; Shelton P
    J Am Pharm Assoc (2003); 2023; 63(1):389-395.e1. PubMed ID: 36369073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacy on-site overdose protocols and prevention of overdose.
    Green TC; Soipe A; Baloy B; Burstein D; Xuan Z; Tapper A; Walley AY; Case P; Bratberg J; Baird J
    Subst Abus; 2022; 43(1):64-68. PubMed ID: 32186478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states.
    Hill LG; Loera LJ; Torrez SB; Puzantian T; Evoy KE; Ventricelli DJ; Eukel HN; Peckham AM; Chen C; Ganetsky VS; Yeung MS; Zagorski CM; Reveles KR
    Drug Alcohol Depend; 2022 Aug; 237():109518. PubMed ID: 35691255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacy naloxone codispensing: A mixed methods study of practices and perspectives under a statewide standing order program.
    Pollini RA; Slocum S; Ozga JE; Joyce R; Xuan Z; Green TC; Walley AY
    J Am Pharm Assoc (2003); 2022; 62(5):1546-1554. PubMed ID: 35450833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rurality and differences in pharmacy characteristics and community factors associated with provision of naloxone in the pharmacy.
    Green TC; Bratberg J; Baird J; Burstein D; Lenz K; Case P; Walley AY; Xuan Z
    Int J Drug Policy; 2020 Nov; 85():102602. PubMed ID: 31740174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naloxone Co-Dispensing with Opioids: a Cluster Randomized Pragmatic Trial.
    Binswanger IA; Rinehart D; Mueller SR; Narwaney KJ; Stowell M; Wagner N; Xu S; Hanratty R; Blum J; McVaney K; Glanz JM
    J Gen Intern Med; 2022 Aug; 37(11):2624-2633. PubMed ID: 35132556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacy staff-reported adaptations to naloxone provision and over-the-counter (OTC) syringe sales during the COVID-19 pandemic: Experiences across multiple states and 2 pharmacy chains.
    Green TC; Silcox J; Bolivar D; Gray M; Floyd AS; Irwin AN; Hansen RN; Hartung DM; Bratberg J
    J Am Pharm Assoc (2003); 2024; 64(1):71-78. PubMed ID: 37863398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacists' naloxone services beyond community pharmacy settings: A systematic review.
    Rawal S; Osae SP; Cobran EK; Albert A; Young HN
    Res Social Adm Pharm; 2023 Feb; 19(2):243-265. PubMed ID: 36156267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ensuring buprenorphine access in rural community pharmacies to prevent overdoses.
    Ostrach B; Potter R; Wilson CG; Carpenter D
    J Am Pharm Assoc (2003); 2022; 62(2):588-597.e2. PubMed ID: 34674965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.
    Bailey AM; Wermeling DP
    Ann Pharmacother; 2014 May; 48(5):601-6. PubMed ID: 24523396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study.
    Slocum S; Ozga JE; Joyce R; Walley AY; Pollini RA
    BMC Public Health; 2022 Apr; 22(1):735. PubMed ID: 35418048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.